Bristol-Myers Bucks Trend Toward Precision Medicine

“Bristol-Myers Squibb Co. has sprinted to an early lead in the race to sell a new class of cancer treatment by bucking the trend toward precision medicine.

“For years, drug companies tried to sell medicines to as many patients as possible. More recently, under pressure from health insurers aiming to improve the odds a costly drug will work, many pharmaceutical companies have been pairing their new therapies with diagnostic tests…”